1. Home
  2. SPRO vs FORR Comparison

SPRO vs FORR Comparison

Compare SPRO & FORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.28

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo Forrester Research Inc.

FORR

Forrester Research Inc.

HOLD

Current Price

$6.30

Market Cap

106.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
FORR
Founded
2013
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
106.6M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
SPRO
FORR
Price
$2.28
$6.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
337.6K
195.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$47,977,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$4.91
52 Week High
$3.09
$11.57

Technical Indicators

Market Signals
Indicator
SPRO
FORR
Relative Strength Index (RSI) 49.92 44.89
Support Level $2.15 $5.02
Resistance Level $2.44 $6.26
Average True Range (ATR) 0.10 0.47
MACD -0.01 0.08
Stochastic Oscillator 55.11 74.65

Price Performance

Historical Comparison
SPRO
FORR

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FORR Forrester Research Inc.

Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.

Share on Social Networks: